The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis. - Wikidata - awgldk - TriplyDB

The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis.

The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q37135295

about

The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer.Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea.Prostate cancer in East Asia: evolving trend over the last decade.Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom.

P2860

Q26786142-35E95920-03A5-4600-8BB0-B27B6F72E03C Q33561563-11DE5040-C140-4E21-93E8-E246BA7CFB1E Q33766472-66914052-0517-4118-AE0A-32443A150D9E Q34927940-D4A5EBC9-42B3-4C32-ACB1-8035799D41F4 Q35583723-A4C18F0C-4769-446B-A5CF-42BC7347077C Q37945643-E7915847-DBD1-4A43-B3DA-5D64C9182404 Q39139831-D6DF8325-39B8-4AAE-A4FF-96544FE2C937 Q43127562-E9A0A3D2-8840-4D59-9C63-79C9D9141D10

P2860

The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q37135295

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The risk of febrile neutropeni ...... atic review and meta-analysis.

@en

The risk of febrile neutropeni ...... atic review and meta-analysis.

@nl

type

label

The risk of febrile neutropeni ...... atic review and meta-analysis.

@en

The risk of febrile neutropeni ...... atic review and meta-analysis.

@nl

prefLabel

The risk of febrile neutropeni ...... atic review and meta-analysis.

@en

The risk of febrile neutropeni ...... atic review and meta-analysis.

@nl

P1433

Q37135295-16D73AD1-FF87-44A0-BDFB-179CE2B54B71

P1476

Q37135295-37006F2E-EE11-49A0-814E-389D82364C53

P2093

Q37135295-2EC8FDF6-F246-48F1-8951-7C52B7949595

Q37135295-77CE1CED-CB16-43D4-9A87-BC542ABA75BD

Q37135295-7A91D7A1-B081-4828-BC1E-DCCC915F4CD9

P2860

Q37135295-0522F11F-6697-429B-9E99-AB340108AE54

Q37135295-2BF27BE5-2FF0-4738-A5DE-09A26C317442

Q37135295-358E5621-1CE2-4CFF-BB0B-D8AFFC8EAE3F

Q37135295-527AF748-EEB3-4530-931A-D70660952597

Q37135295-75153DD2-5923-412A-9F22-EECD21D20720

Q37135295-86640083-4B8E-48C4-A6DD-6CC0D0A245D2

Q37135295-8C291211-0946-49A0-8FAB-668AF2706A65

Q37135295-8E4ADC26-8735-4622-B4EF-35E4B7352DE4

Q37135295-A7035804-F402-414F-8CE0-4B9DA1FD9570

Q37135295-BDBF9B7F-FC32-43E0-9798-32E06FA0A303

P2888

Q37135295-011BEE7F-F5B4-4CC0-9B70-23E62FFC1745

P304

Q37135295-42DB6B24-1C3B-403B-8053-D01A866B2E4F

P31

Q37135295-0df1e6bc-f423-4066-b70d-c8d1c6489132

Q37135295-BDA28CFB-85E2-4036-929C-DC217DE12453

Q37135295-C8D397CE-08D4-4987-81E3-A9E2E7024C4F

P356

Q37135295-8810CD01-4230-4139-9406-27AA3EBD805B

P407

Q37135295-BCE2C4E8-166A-4097-BA11-62559D956FCF

P433

Q37135295-47CE6419-84C8-4096-A997-DD43CBCA17F4

P478

Q37135295-A2F62882-466B-4F9D-A29F-4B3AA3710E37

P577

Q37135295-247B44F3-9C00-41F8-8A33-6D0661315507

Q37135295-2AFA84CB-60E9-43FB-950F-5928941512A6

P5875

Q37135295-14FEA1CE-58B4-4348-AD2B-017DE30DCE87

P698

Q37135295-800652D5-4F19-4D54-9607-84ECA62CB4A8

P921

Q37135295-1CC621C1-056B-4316-8B11-11B349990B1A

Q37135295-4091425B-5F99-4193-B2F9-356EEF1413B9

Q37135295-7F3D6139-9D11-4E3F-B717-15A4A08DAA70

Q37135295-CEC2B27C-E311-4F94-A99A-2A798703AE09

Q37135295-DCD2584D-7BD1-4C8E-A9DE-EE7972CC1CF5

Q37135295-FADD3EE5-9973-41EA-BC8C-D7AC7F6B0A79

P932

Q37135295-384C4337-1530-4BCC-B8F1-F64E9FA73E39

P356

P1433

British Journal of Cancer

P1476

The risk of febrile neutropeni ...... atic review and meta-analysis.

@en

P2093

A Morgan

http://www.w3.org/2001/XMLSchema#string

A Sutton

http://www.w3.org/2001/XMLSchema#string

A Wailoo

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.

Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).

P2888

P304

436-441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604863

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2009-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23974885

http://www.w3.org/2001/XMLSchema#string

P698

19190633

http://www.w3.org/2001/XMLSchema#string

P921

non-small-cell lung carcinoma

P932

2658551

http://www.w3.org/2001/XMLSchema#string